Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Aimmune Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Aimmune Therapeutics for you to read. Along with our medical data and news we also list Aimmune Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aimmune Therapeutics Companies for you to search.
www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million Read more...
Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: RARE) in Novato, CA. Dallas succeeds Stephen Dilly, who last year announced his plans to retire from Aimmune. The company says Dilly will continue to serve as an […]
An initial jump has been followed by a deeper drop in the share value of US biotech Aimmune Therapeutics…
BRISBANE, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that the results of its...
Stock Monitor: Cyanotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Aimmune Therapeutics, Inc. (NASDAQ: A...
US biotech Aimmune Therapeutics has published full results from its 554-patient Phase III PALISADE trial…
Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV Technologies and Aimmune Therapeutics—presented to investors at...Read More... The post DBV and Aimmune poised to dominate peanut allergy market appeared first on Drug Development Technology.
Peanuts rank among the top foods that spark allergic reactions, prompting schools to ban peanut butter sandwiches and travelers to decline airline snacks. Aimmune Therapeutics aims to help with a drug that makes people less sensitive to peanuts. On Tuesday, Aimmune (NASDAQ: AIMT) announced that its drug met the main goals of a late-stage study, […]
A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
Aimmune Therapeutics announced late-stage trial results that showed its peanut allergy therapy was effective in more than 67 percent of juvenile patients.
— Presentation on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference in ...
Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $165mm through a public offering of 5.5mm common shares at $3...
Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $190mm through a public offering of 6.3mm common shares (incl...
(Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.
Biotech company Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following its major phase 3 trial success. Aimmune saw its shares surge last month after the positive topline results from its PALISA...
(Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event: Bank of America Merrill Lynch Healthcare ConferenceDate: May 16, 2018P...
The peanut allergy space heats up as Aimmune reports strong data for its late-stage treatment.
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in March: Event: 30th Annual ROTH ConferenceDate: Monday, March 12, 2018Presentation Time: 3:3...